{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T09:54:18Z","timestamp":1769507658120,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40256-024-00658-0","type":"journal-article","created":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T11:01:37Z","timestamp":1719054097000},"page":"481-504","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Ongoing and Future Clinical Trials of Pharmacotherapy for Heart Failure"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0447-7186","authenticated-orcid":false,"given":"Taha","family":"Mansoor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subaina N.","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Ibraiz","family":"Bilal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sardar Hassan","family":"Ijaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marat","family":"Fudim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Greene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haider J.","family":"Warraich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay","family":"Nambi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salim S.","family":"Virani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitry","family":"Abramov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul Mannan Khan","family":"Minhas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,22]]},"reference":[{"key":"658_CR1","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1056\/NEJM199711063371906","volume":"337","author":"E Ugene","year":"1997","unstructured":"Ugene E, Raunwald B. Cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med. 1997;337:1360\u20139. https:\/\/doi.org\/10.1056\/NEJM199711063371906.","journal-title":"N Engl J Med"},{"key":"658_CR2","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1161\/CIRCRESAHA.121.318172","volume":"128","author":"VL Roger","year":"2021","unstructured":"Roger VL. Epidemiology of heart failure: a contemporary perspective. Circ Res. 2021;128:1421\u201334.","journal-title":"Circ Res"},{"key":"658_CR3","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1001\/jamacardio.2024.0615","volume":"9","author":"A Sayed","year":"2024","unstructured":"Sayed A, Abramov D, Fonarow GC, Mamas MA, Kobo O, Butler J, et al. Reversals in the decline of heart failure mortality in the US, 1999\u20132021. JAMA Cardiol. 2024;9:585.","journal-title":"JAMA Cardiol"},{"key":"658_CR4","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.cardfail.2023.07.006","volume":"29","author":"B Bozkurt","year":"2023","unstructured":"Bozkurt B, Ahmad T, Alexander KM, Baker WL, Bosak K, Breathett K, et al. Heart failure epidemiology and outcomes statistics: a report of the heart failure society of America. J Card Fail. 2023;29:1412\u201351.","journal-title":"J Card Fail"},{"key":"658_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijcard.2022.01.004","volume":"350","author":"E Carluccio","year":"2022","unstructured":"Carluccio E, Dini FL, Bitto R, Ciccarelli M, Correale M, D\u2019Agostino A, et al. Benefit from sacubitril\/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: an echocardiographic study. Int J Cardiol. 2022;350:62\u20138.","journal-title":"Int J Cardiol"},{"key":"658_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijcard.2022.01.035","volume":"353","author":"E Donal","year":"2022","unstructured":"Donal E, L\u2019official G, Kosmala W. New guidelines for managing chronic heart failure patients and new needs in echocardiography. Int J Cardiol. 2022;353:71\u20132.","journal-title":"Int J Cardiol"},{"key":"658_CR7","first-page":"E895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:E895-1032.","journal-title":"Circulation"},{"key":"658_CR8","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2022190.","journal-title":"N Engl J Med"},{"key":"658_CR9","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","volume":"81","author":"BA Borlaug","year":"2023","unstructured":"Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart failure with preserved ejection fraction: JACC scientific statement. J Am Coll Cardiol. 2023;81:1810\u201334.","journal-title":"J Am Coll Cardiol"},{"key":"658_CR10","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"key":"658_CR11","first-page":"605","volume":"3","author":"AB Miller","year":"2007","unstructured":"Miller AB. Aldosterone antagonism in heart failure. Vasc Health Risk Manag. 2007;3:605.","journal-title":"Vasc Health Risk Manag"},{"key":"658_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/cts.12705","volume":"13","author":"A Whittaker","year":"2020","unstructured":"Whittaker A, Kragh \u00c5M, Hartleib-Geschwindner J, Albayaty M, Backlund A, Greasley PJ, et al. Safety, tolerability, and pharmacokinetics of the mineralocorticoid receptor modulator AZD9977 in healthy men: a phase i multiple ascending dose study. Clin Transl Sci. 2020;13:275\u201383.","journal-title":"Clin Transl Sci"},{"key":"658_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11897-019-0424-1","volume":"16","author":"R Gupta","year":"2019","unstructured":"Gupta R, Testani J, Collins S. Diuretic resistance in heart failure. Curr Heart Fail Rep. 2019;16:57\u201366.","journal-title":"Curr Heart Fail Rep"},{"key":"658_CR14","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","volume":"387","author":"W Mullens","year":"2022","unstructured":"Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, et al. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med. 2022;387:1185\u201395.","journal-title":"N Engl J Med"},{"key":"658_CR15","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1056\/NEJMe2209997","volume":"387","author":"GM Felker","year":"2022","unstructured":"Felker GM. New decongestion strategies in an evolving heart failure landscape. N Engl J Med. 2022;387:1231\u20133. https:\/\/doi.org\/10.1056\/NEJMe2209997.","journal-title":"N Engl J Med"},{"key":"658_CR16","volume":"36","author":"IG Halatchev","year":"2021","unstructured":"Halatchev IG, Wu WC, Heidenreich PA, Djukic E, Balasubramanian S, Ohlms KB, et al. Inpatient versus outpatient intravenous diuresis for the acute exacerbation of chronic heart failure. Int J Cardiol Heart Vasc. 2021;36: 100860.","journal-title":"Int J Cardiol Heart Vasc"},{"key":"658_CR17","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/ejhf.71","volume":"16","author":"H Skali","year":"2014","unstructured":"Skali H, Dwyer EM, Goldstein R, Haigney M, Krone R, Kukin M, et al. Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT. Eur J Heart Fail. 2014;16:560\u20135.","journal-title":"Eur J Heart Fail"},{"key":"658_CR18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/clc.22473","volume":"39","author":"WL Jiang","year":"2016","unstructured":"Jiang WL, Gu HB, Zhang YF, Xia QQ, Qi J, Chen JC. Vitamin D supplementation in the treatment of chronic heart failure: a meta-analysis of randomized controlled trials. Clin Cardiol. 2016;39:56\u201361.","journal-title":"Clin Cardiol"},{"key":"658_CR19","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/ajcn\/83.4.754","volume":"83","author":"SS Schleithoff","year":"2006","unstructured":"Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006;83:754\u20139.","journal-title":"Am J Clin Nutr"},{"key":"658_CR20","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1159\/000429325","volume":"41","author":"P Coratelli","year":"1984","unstructured":"Coratelli P, Petrarulo F, Buongiorno E, Giannattasio M, Antonelli G, Amerio A. Improvement in left ventricular function during treatment of hemodialysis patients with 25-OHD3. Contrib Nephrol. 1984;41:433\u20137.","journal-title":"Contrib Nephrol"},{"key":"658_CR21","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1161\/CIRCULATIONAHA.118.036459","volume":"139","author":"R Nielsen","year":"2019","unstructured":"Nielsen R, M\u00f8ller N, Gormsen LC, Tolbod LP, Hansson NH, Sorensen J, et al. Cardiovascular effects of treatment with the ketone body 3-hydroxybutyrate in chronic heart failure patients. Circulation. 2019;139:2129\u201341.","journal-title":"Circulation"},{"key":"658_CR22","doi-asserted-by":"publisher","first-page":"17328","DOI":"10.1021\/acs.iecr.1c03074","volume":"60","author":"S Banerjee","year":"2021","unstructured":"Banerjee S, Mwangi JG, Stanley TK, Mitra R, Ebong EE. Regeneration and assessment of the endothelial glycocalyx to address cardiovascular disease. Ind Eng Chem Res. 2021;60:17328\u201347.","journal-title":"Ind Eng Chem Res"},{"key":"658_CR23","unstructured":"Fukaya E, Gloviczki ML. An introduction to endothelial glycocalyx-what is it and why does it matter?"},{"key":"658_CR24","doi-asserted-by":"crossref","unstructured":"The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525\u201333. https:\/\/pubmed.ncbi.nlm.nih.gov\/9036306\/. Cited 22 Apr 2024.","DOI":"10.1056\/NEJM199702203360801"},{"key":"658_CR25","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","volume":"298","author":"AM Lincoff","year":"2007","unstructured":"Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298:1180\u20138.","journal-title":"JAMA"},{"key":"658_CR26","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","volume":"374","author":"WN Kernan","year":"2016","unstructured":"Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374:1321\u201331.","journal-title":"N Engl J Med"},{"key":"658_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-17327-4","volume":"12","author":"J Benes","year":"2022","unstructured":"Benes J, Kotrc M, Kroupova K, Wohlfahrt P, Kovar J, Franekova J, et al. Metformin treatment is associated with improved outcome in patients with diabetes and advanced heart failure (HFrEF). Sci Rep. 2022;12: 13038.","journal-title":"Sci Rep"},{"key":"658_CR28","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1177\/107424849800300407","volume":"3","author":"GN Jyothirmayi","year":"1998","unstructured":"Jyothirmayi GN, Soni BJ, Masurekar M, Lyons M, Regan TJ. Effects of metformin on collagen glycation and diastolic dysfunction in diabetic myocardium. J Cardiovasc Pharmacol Therap. 1998;3:319\u201326. https:\/\/doi.org\/10.1177\/107424849800300407.","journal-title":"J Cardiovasc Pharmacol Therap"},{"key":"658_CR29","doi-asserted-by":"publisher","first-page":"01100","DOI":"10.1186\/s12933-020-01100-w","volume":"19","author":"A Halabi","year":"2020","unstructured":"Halabi A, Sen J, Huynh Q, Marwick TH. Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis. Cardiovasc Diabetol. 2020;19:01100.","journal-title":"Cardiovasc Diabetol"},{"key":"658_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1253\/circj.70.1","volume":"70","author":"S Sasayama","year":"2006","unstructured":"Sasayama S, Izumi T, Seino Y, Ueshima K, Asanoi H. Effects of nocturnal oxygen therapy on outcome measures in patients with chronic heart failure and cheyne-stokes respiration. Circ J. 2006;70:1\u20137.","journal-title":"Circ J"},{"key":"658_CR31","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1152\/japplphysiol.00850.2019","volume":"128","author":"MN Woessner","year":"2020","unstructured":"Woessner MN, Neil C, Saner NJ, Goodman CA, McIlvenna LC, De Zevallos JO, et al. Effect of inorganic nitrate on exercise capacity, mitochondria respiration, and vascular function in heart failure with reduced ejection fraction. J Appl Physiol. 2020;128:1355\u201364.","journal-title":"J Appl Physiol"},{"key":"658_CR32","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1152\/ajpregu.00263.2016","volume":"312","author":"DM Hirai","year":"2017","unstructured":"Hirai DM, Zelt JT, Jones JH, Castanhas LG, Bentley RF, Earle W, et al. Dietary nitrate supplementation and exercise tolerance in patients with heart failure with reduced ejection fraction. Am J Physiol Regul Integr Comp Physiol. 2017;312:R13-22.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"658_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvab069","volume":"7","author":"U Kansakar","year":"2021","unstructured":"Kansakar U, Varzideh F, Jankauskas SS, Gambardella J, Trimarco B, Santulli G. Advances in the understanding of excitation-contraction coupling: the pulsing quest for drugs against heart failure and arrhythmias. Eur Heart J Cardiovasc Pharmacother. 2021;7: e91.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"658_CR34","unstructured":"PW A, B P, KJ A, J E, AF H, J B, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 2020;382. https:\/\/pubmed.ncbi.nlm.nih.gov\/32222134\/. Cited 22 Apr 2024."},{"key":"658_CR35","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/ndt\/gfab191","volume":"36","author":"J Barratt","year":"2021","unstructured":"Barratt J, Andric B, Tataradze A, Sch\u00f6mig M, Reusch M, Valluri U, et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, open-label, active-controlled study (DOLOMITES). Nephrol Dial Transplant. 2021;36:1616\u201328.","journal-title":"Nephrol Dial Transplant"},{"key":"658_CR36","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1111\/bph.16055","volume":"180","author":"P Verdino","year":"2023","unstructured":"Verdino P, Lee SL, Cooper FN, Cottle SR, Grealish PF, Hu CC, et al. Development of a long-acting relaxin analogue, LY3540378, for treatment of chronic heart failure. Br J Pharmacol. 2023;180:1965\u201380.","journal-title":"Br J Pharmacol"},{"key":"658_CR37","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/eurheartj\/ehaa791","volume":"42","author":"S Batkai","year":"2021","unstructured":"Batkai S, Genschel C, Viereck J, Rump S, B\u00e4r C, Borchert T, et al. CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure. Eur Heart J. 2021;42:192.","journal-title":"Eur Heart J"},{"key":"658_CR38","unstructured":"Nieminen M, Fruhwald S, Heart LH-, and lung, 2013 undefined. Levosimendan: current data, clinical use and future development. ncbi.nlm.nih.govMS Nieminen, S Fruhwald, LMA Heunks, PK Suominen, AC Gordon, M Kivikko, P PolleselloHeart, lung and vessels, 2013 ncbi.nlm.nih.gov [Internet]. [cited 2024 Apr 22]; https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3868185\/. Cited 22 Apr 2024."},{"key":"658_CR39","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jjcc.2022.11.001","volume":"81","author":"K Kida","year":"2023","unstructured":"Kida K, Miyajima I, Suzuki N, Greenberg BH, Akashi YJ. Nutritional management of heart failure. J Cardiol. 2023;81:283\u201391.","journal-title":"J Cardiol"},{"key":"658_CR40","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.1002\/ehf2.13646","volume":"8","author":"A Abdin","year":"2021","unstructured":"Abdin A, Anker SD, Butler J, Coats AJS, Kindermann I, Lainscak M, et al. \u201cTime is prognosis\u201d in heart failure: time-to-treatment initiation as a modifiable risk factor. ESC Heart Fail. 2021;8:4444\u201353.","journal-title":"ESC Heart Fail."},{"key":"658_CR41","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jacc.2022.11.023","volume":"81","author":"SJ Greene","year":"2023","unstructured":"Greene SJ, Bauersachs J, Brugts JJ, Ezekowitz JA, Lam CSP, Lund LH, et al. Worsening heart failure: nomenclature, epidemiology, and future directions: JACC review topic of the week. J Am Coll Cardiol. 2023;81:413\u201324.","journal-title":"J Am Coll Cardiol"},{"key":"658_CR42","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5:632.","journal-title":"JACC Basic Transl Sci"},{"key":"658_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fcdhc.2023.1293926","volume":"4","author":"L Ferhatbegovi\u0107","year":"2023","unstructured":"Ferhatbegovi\u0107 L, Mr\u0161i\u0107 D, Maci\u0107-D\u017eankovi\u0107 A. The benefits of GLP1 receptors in cardiovascular diseases. Front Clin Diabetes Health care. 2023;4: 1293926.","journal-title":"Front Clin Diabetes Health care"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00658-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-024-00658-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00658-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T07:29:40Z","timestamp":1720510180000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-024-00658-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,22]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["658"],"URL":"https:\/\/doi.org\/10.1007\/s40256-024-00658-0","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,22]]},"assertion":[{"value":"30 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Fonarow reports consulting for Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Eli Lilly, Johnson & Johnson, Medtronic, Merck, Novartis, and Pfizer. Dr. Greene has received research support from the Duke University Department of Medicine Chair\u2019s Research Award, American Heart Association (#929502), National Heart Lung and Blood Institute, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer, and Sanofi; has served on advisory boards for Amgen, AstraZeneca, Boehringer Ingelheim\/ Lilly, Bristol Myers Squibb, Cytokinetics, Roche Diagnostics, scPharmaecuticals, and Sanofi; serves as a consultant for Amgen, Bayer, Bristol Myers Squibb, Corteria Pharmaceuticals, CSL Vifor, Lexicon Pharmaceuticals, PharmaIN, Roche Diagnostics, Sanofi, scPharmaceuticals, Tricog Health, Urovant Pharmaceuticals; and has received speaker fees from Bayer, Boehringer Ingelheim, Cytokinetics, Lexicon, and Roche Diagnostics. Dr. Dmitry Abramov has received speaker fees from Bayer and AstraZeneca. Dr. Virani: Grant support from the Department of Veterans Affairs, NIH, Tahir and Jooma Family. Honorarium: American College of Cardiology (Associate Editor for Innovations, acc.org- ended June 2021). No relationships with industry to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Clinicaltrials.gov.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Data extraction, writing: TM. Writing: SNK, MIB. Reviewing and editing: SHI, MF, SJG, HJW, VN, SSV, GCF, DA. Conceptualizing, reviewing, editing, and supervision: AMKM.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for participation"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}